TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					11	cket No. 26.25.1		
In Re A	n Re Application Of: William J. Ketcherside, Jr., et al.							
Application No. Filing Date Examiner Examiner No. Group Art Unit Confirmation No.								
10/	773,106	02/05/2004	POPE, DARYL C	022913	2632	3980		
Title:		IETHOD, AND COM INFORMATION SY	IPUTER PROGRAM FOR INT STEM	ERFACING AN	N EXPERT SYST	ГЕМ ТО A		
			Address to: Commissioner for Paten P.O. Box 1450 Alexandria, VA 22313-14					
			37 CFR 1.97(b)					
1.	of a nation three mon application	nal application other ths of the date of en ; before the mailing o	tement submitted herewith is than a continued prosecution try of the national stage as set of a first Office Action on the most for continued examination under the continued examination unde	application und t forth in 37 CF nerits, or before	der 37 CFR 1.53 R 1.491 in an in the mailing of a	B(d); within ternational		
 The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: 								
	☐ the	statement specified in	n 37 CFR 1.97(e);					
	OR							
☐ the fee set forth in 37 CFR 1.17(p).								

TRANSMITTA	AL OF INFORMA (Under 37 CFI	ATION DISCLOS R 1.97(b) or 1.97(d	/0	TEMENT E		cket No. 26.25.1	
In Re Application o	f: William J. Ketc	herside, Jr., et al.	\3	7 2006 14			
Application No.	Filing Date	Examiner	\'77	omer No.	Group Art Unit	Confirmation No.	
10/773,106	02/05/2004	POPE, DARY	L C	022913	2632	3980	
•	METHOD, AND COM INFORMATION SY		1 FOR INT	ERFACING AN	N EXPERT SYST	ГЕМ ТО А	
	(Only con	Payme	ent of Fee s to pay the f	ee set forth in 37	CFR 1.17(p))		
☐ The Director as describer ☐ Ch☐ ☐ Ch☐ ☐ Ch☐ ☐ Ch☐ ☐ Ch☐ ☐ ☐ Ch☐ ☐ MARNING	the amount of or is hereby authorized below. arge the amount of edit any overpayment arge any additional for y credit card. Form P : Information on thi	is attached to charge and cred t. ee required. TO-2038 is attached s form may become	ned. dit Deposit A	Account No. 2	23-3178 ermation should	I not be	
Certificate of Transmission by Facsimile* Certificate of Transmission by Facsimile* Certificate of Mailing by First Class Mail I certify that this document and authorization to charge deposition account is being facsimile transmitted to the United States Patent and Trademark Office (Fa Signature Signature Signature *This certificate may only be used if paying by deposit account. Dated: June 27, 2006							
Signature FRASER D. ROY Attorney for Applicants Registration No. 45,666 Customer No. 022913							

CC:

EXPRESS MAIL LABEL NO.: EV 912 289 275 US

PATENT APPLICATION Docket No.: 15226.25.1

	IN THE UNIT	ED STATES PATENT AND TRADEMARK OFFI	CE
Tre applicat	tion of:)
		William J. Ketcherside, Jr., et al.)
Serial No.:		10/773,106) Art Unit) 2632
Filed:	·	February 5, 2004)
Confirmation	ı No.:	3980)
For:		SYSTEM, METHOD, AND COMPUTER PROGRAM FOR INTERFACING AN EXPERT)))

SYSTEM

022913

Daryl C. Pope

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Examiner:

Customer No.:

Please find, pursuant to 37 C.F.R. § 1.98(a)(1), the enclosed Form PTO-1449 which contains a list of all patents, publications, or other items that have come to the attention of one or more of the individuals designated in 37 C.F.R. § 1.56(c). While no representation is made that any of these references may be "prior art" within the meaning of that term under 35 U.S.C. §§

06/29/2006 CCHAU1

00000024 10773106

02 FC:1806

180.00 DP

102 or 103, the enclosed list of references is disclosed so as to fully comply with the duty of

disclosure set forth in 37 C.F.R. § 1.56.

Moreover, while no representation is made that a specific search of office files or patent

office records has been conducted or that no better art exists, the undersigned attorney of record

believes that the enclosed art is the closest to the claimed invention (taken in its entirety) of

which the undersigned is presently aware, and no art which is closer to the claimed invention

(taken in its entirety) has been knowingly withheld.

In accordance with 37 C.F.R. §§ 1.97 and 1.98, a copy of each of the listed references or

relevant portion thereof is also enclosed.

Dated this 27th day of June, 2006.

Respectfully submitted,

FRASER D. ROY

Attorney for Applicant Registration No. 45,666

Customer No. 022913

FDR:kc

KC0000005983V001

2

	OLP E W			Sheet 1 of 6
FORM PTO-1449	UN 2 7 2006 W	Atty. Docket No.: 15226.25.1	Serial No.: 10/773,106	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATIONDISCLOSURE		Applicant: William J. Ketcherside, Jr. et al.		
STAT	EMENT	Filing Date:	Group Art:	
		02/05/2004	2632	
			1	

U.S. PATENTS

Examii Initia		Date	Name	Class	Sub Class	Filing Date If Appropriate
	6,188,988	02/13/2001	Barry et al.	705	3	03/10/2000
	6,081,786	06/27/2000	Barry et al.	705	3	04/01/1999

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial	Document No.	Date	Name	Class	Sub Class	Filing Date If Appropriate
	2004/0260666	12/23/2004	Pestotnik et al.	706	46	09/09/2003
	2002/0002472	01/03/2002	Abraham-Fuchs et al.	705	3	04/18/2001

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

"ADE Assistant." www.theradoc.com . November 13, 2005. http://www.theradoc.com/products_products_ade.html
"Antibiotic Assistant – Antibiotic Assistant Overview." <u>www.theradoc.com</u> . November 13, 2005. http://www.theradoc.com/products/products_abxassist.html >
"Antibiotic Assistant – Integrated Model." <u>www.theradoc.com</u> . November 13, 2005. http://www.theradoc.com/products/products_integrated.html >
Bates DW, et al., "The Costs of Adverse Drug Events in Hospitalized Patients. Adverse Drug Events Prevention Study Group," <u>JAMA</u> 277.4 (January 22, 1997): 1 http://jama.ama-assn.org/cgi/content/abstract/277/4/307 >
Burke JP, "Hospitals Enter the War Against Antibiotic Resistance," [editorial review] <u>Current Opinion on Infectious Diseases</u> 8 (1995): 269-271
Burke JP, et al., "A Retrospective Analysis of Twice-daily Cefotaxime Compared to Convetional Therapy for the Treatment of Infections in a USA Hospital," <u>Diagn Microbial Infect Dis</u> 22 (1995):167-69
Burke JP, et al., "Antibiotic Cycling: What Goes Around Comes Around," [editorial review] Current Opinion in Infectious Diseases 13 (2000): 367-69

EXAMINER: DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		Atty. Docket No.: 15226.25.1	Serial No.: 10/773,106	
		Applicant:		
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATIONDISCLOSURE		William J. Ketcherside, Jr. e	t al.	
	STATEMENT	Filing Date:	Group Art:	
		02/05/2004	2632	
	Burke JP, et al., "Antibiotic Resistanc Infectious Diseases 11 (1998): 441-43	e: The Combat Zone," [editor	rial review] Current Opinion in	
	Burke JP, et al., "Antibiotic Resist [editorial review] Current Opinion in I			
	Burke JP, et al., "Breaking the Chain of Antibiotic Resistance," [editorial review] Current Opin in Infectious Diseases 9 (1996): 253-55			
	Burke JP, et al., "Evaluation of the Financial Impact of Ketorolac Tromethamine Therapy in Hospitalized Patients," Rpt. from Clinical Therapeutics 18.1 (1996): 197-211			
	Burke JP, et al., "Evaluation of the Impact of Implementation of a Comprehensive Computerized Antibiotic Management Program at Intermountain Health Care," Healthcare Information and Management Systems Society Proceedings 1 (1997): 18-24			
	Burke JP, et al., "Evaluation of Therapeutic Antibiotic Substitution by Microcosting Using Automated Hospital Database," Abstracts of the 1991 ICAAC, The 31 st Interscience Conference Antimicrobial Agents and Chemotherapy. Chicago, IL (September 29 – October 2, 1991), Artic 407: 167			
	Burke JP, et al., "Inappropriate Ant Clinical Research 36.1 (January 1988):		Using Computer Algorithms,"	
	Burke JP, et al., "The HELP System a Infection 18(Supp. A) (1991): 424-31	and Its Application to Infection	n Control," <u>Journal of Hospital</u>	
	Burke JP, et al., "The Pharmacy and D Clinicians. Baltimore: Williams & Wil	orug Usage," <u>Assessing Qualit</u> kins (1991): 509-20	y Health Care: Perspectives for	
	Burke JP, et al., "The Quality of Antibiotic Use and the Quality of Measuring It," [editorial review] Current Opinion in Infectious Diseases 10 (1997: 289-291			
	Burke JP, et al., Reply to Letters. <u>JAMA</u> 277.17 (May 7, 1997): 1351-1353			
	Classen DC, et al., "Adverse Drug Events in Hospitalized Patients: Excess Length of Stay, Extra Costs, and Attributable Mortality," JAMA 277.4 (January 1997): 301-6			
	Classen DC, et al., "Adverse Effects of Intravenous Erythromycin in Hospital Patients: Attributable Costs and Excess Length of Stay," Abstracts of the 36 th ICAAC, American Society for Microbiology, New Orleans, Louisiana, Session 112 (September 15-18, 1996): Article N19: 296			
	Classen DC, et al., "Antibiotic Prophy England Journal of Medicine 327.3 (Ju		ections," [To the Editor:] New	
	Classen DC, et al., "Case 12.1: LDS Hospital: Institution-Wide Antibiotic Management," Transforming Health Care Through Information Case Studies. NM Lorenzi, et al. Ed. Springer-Verlag New York NV (1995): 322-332			

FORM	I PTO-1449	Atty. Docket No.: 15226.25.1	Serial No.: 10/773,106		
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATIONDISCLOSURE		Applicant: William J. Ketcherside, Jr. et al.			
	STATEMENT	Filing Date: 02/05/2004	Group Art: 2632		
	Classen DC, et al., "Clinical and H Hospitalized Patients," Annals of Phar	Financial Impact of Intravenomacotherapy 33 (June 1999):	ous Erythromycin Therapy in 669-73		
	Classen DC, et al., "Clinical Evaluation Teaching Hospital," Abstracts of the Antimicrobial Agents and Chemothera	on of a Computerized Antibioti he 1992 ICAAC, The 32 ^{nc}	c Selection Program in a Large Interscience Conference on		
		Classen DC, et al., "Computerized Surveillance of Adverse Drug Events in Hospitalized Patient JAMA 266.20 (November 27, 1991): 2847-51			
	Classen DC, et al., "Description of a Computerized Adverse Drug Event Monitor Using a Ho Information System," Hospital Pharmacy 27 (September 1992):774, 776-779, 783				
	Classen DC, et al., "Intensive Surveillance of Midazolam Use in Hospital Patients and the Occurrence of Cardiorespiratory Arrest," 12.3 Pharmacotherapy (1992): 213-16				
	Classen DC, et al., "Prophylactic Antibiotics Used to Prevent Surgical Wound Infections," <u>Clir Practice Improvement: A New Technology for Developing Cost-Effective Quality Health Control New York: Faulkner & Gray (1994): 217-21</u>				
	Classen DC, et al., "Surveillance for Information System," 12.4 Infection C				
		Classen DC, et al., "The Computer-Based Patient Record: An Essential Technology for Hospi Epidemiology," <u>Hospital Epidemiology and Infection Control</u> Ed. CG Mayhall, Williams Williams, Baltimore, MD (1996): 123-137			
	Disease: Strategies for Managing Cl Antimicrobial Agents and Chemoth	Classen DC, et al., "The Impact of Managed Care and Capitation on the Practice of Infectious Disease: Strategies for Managing Clinical Care," Abstracts – 35 th Interscience Conference on Antimicrobial Agents and Chemotherapy an Annual Meeting of the American Society for Microbiology San Francisco, CA (September 17-20, 1995): Article S19: 352			
		Classen DC, et al., "The Timing of Prophylactic Administration of Antibiotics and the Risk of Surgical-wound Infections," New England Journal of Medicine 326.5 (January 30, 1992): 281-86			
	Epidemiology," Hospital Epidemiolog	Classen, DC, et al., "The Computer-Based Patient Record: An Essential Technology for Hospital Epidemiology," <u>Hospital Epidemiology and Infection Control 2E.</u> Ed. C. Glen Mayhall. Lippiacott Williams & Williams, Philadelphia, PA (1999): 141-154			
	Evans RS, et al., "A Computerized A Symp Comput Appl Med Care 11 (198	Approach to Monitor Prophylactic Antibiotics," <u>Proc Annu</u> 87): 241-45			
	Evans RS, et al., "A Decision Suppo Appl Med Care 19 (1995): 651-55	ort Tool for Antibiotic Therap	Tool for Antibiotic Therapy," Proc Annu Symp Comput		
	Evans RS, et al., "Applications of Medical Informatics in Antibiotic Therapy," Antimic Susceptibility Testing 349 (1994): 87-96				

FORM PTO-1449		Atty. Docket No.: 15226.25.1	Serial No.: 10/773,106	
		Applicant:		
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATIONDISCLOSURE		William J. Ketcherside, Jr. e	t al.	
	STATEMENT	Filing Date:	Group Art:	
		02/05/2004	2632	
	Evans RS, et al., "Computer Surveil <u>JAMA</u> 256.8 (August 22/29, 1986): 10		nfections and Antibiotic Use,"	
	Evans RS, et al., "Computerized Ide Infections," <u>American Journal of Infec</u>			
	Evans RS, et al., "Development of a Symp Comput Appl Med Care 15 (199		g Event Monitor," Proc Annu	
	Evans RS, et al., "Development of an Automated Antibiotic Consultant," M.D. Computing 1 (1993): 17-22			
	Evans RS, et al., "Evaluating the Impact of Computer-based Drug Monitoring on the Quality and Cost of Drug Therapy," <u>Hospital Information Systems</u> (1995): 201-220			
	Evans RS, et al., "Evaluating the Impact of Computer-based Drug Monitoring on the Quality ar Cost of Drug Therapy," <u>Hospital Information Systems: Design and Development Characteristic Impact and Future Architecture</u> . Medical Artificial Intelligence Series. Amsterdam: Elsevier. (1998): 1-20			
	Evans RS, et al., "Experience with a Computer-Assisted Antiinfective Agent Manageme Program," Computer-Assisted Decision-Making Activated by Clinical Laboratory Findings. C Chem Lab Med Symposium Abstracts – IFCC-WorldLab '99. Firenze. 37 – Special Suppleme (June 6-11, 1999): S6			
	Evans RS, et al., "Improving Empiri Arch Intern Med 154 (April 25, 1994):	c Antibiotic Selection Using 878-84	Computer Decision Support,"	
	Evans RS, et al., "Prediction of H Automated Hospital Database," Proc A			
	Evans RS, et al., "Preventing Adverse Drug Events in Hospitalized Patients," Annals of Pharmacotherapy 28 (April 1994): 523-527			
	Evans RS, et al., "Prevention of Adve Annu Symp Copmut Appl Med Care 1		mputerized Surveillance," Proc	
	Evans RS, et al., "Reducing the Durati of Surgical Patients," <u>DICP</u> , The Annu			
	Evans RS, et al., "The Evaluation of Information Services, Departments o LDS Hospital and University of Utah S	f Medical Informatics, Infect	ious Diseases, and Pharmacy,	
	Evans RS, et al., "Using a Hospital Events," Proc Annu Symp Comput Ap	Information System to Assess the Effects of Adverse Drug opl Med Care 17 (1993): 161-65		

FORM	1 PTO-1449	Atty. Docket No.: 15226.25.1	Serial No.: 10/773,106			
		Applicant:				
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATIONDISCLOSURE STATEMENT		William J. Ketcherside, Jr. et al.				
		Filing Date:	Group Art:			
		02/05/2004	2632			
	Gundlapalli AV, et al., "A Rule-based Deployment by a Hospital Infection C as early as 2001					
	Gundlapalli AV, et al., "Hospital El System Deployed During the 2002 W Conference, San Antonio, TX, Session	inter Olympic Games," Prese				
·	Harbarth S, et al., "Clinical and Econo Nephrotoxicity," <u>CID</u> 35 (December 1		nal Amphotericin B-Associated			
	Harbarth S, et al., "The Epidemi Amphotericin B Therapy," American J	Harbarth S, et al., "The Epidemiology of Nephrotoxicity Associated with Conventional Amphotericin B Therapy," American Journal of Medicine 111 (November 2001): 528-534				
		Hongsermeier TM, et al., "TheraDoc Expert Systems: The Cornerstone of a Successful Infection Management and Patient Safety Strategy," White Paper, Salt Lake City: TheraDoc, Inc. (2003): 1-10				
		Kelly DL, et al., "Reengineering a Surgical Service Line: Focusing on Core Process Improvement, American Journal of Medical Quality 12.2 (1997): 120-29				
		Larsen RA, et al., "Improved Perioperative Antibiotic Use and Reduced Surgical Wound Infection Through Use of Computer Decision Analysis," <u>Infect Control Hosp Epidemiol</u> 10.7 (1989): 3 320				
		Leader WG, et al., "Integrating Pharmacokinetics into Point-of-Care Information Systems," Clin Pharmacokinet. 31.3 (September 1996): 165-173				
	[Abstract]," American Society for Mic	Lo TS., et al., "Secular Trends of Enterococcal Urinary Tract Infection: A Ten-Year Study [Abstract]," American Society for Microbiology, 1 st International ASM Conference on Enterococci, available at least as early as December 6, 1999: 1				
		Naranjo CA, et al., "A Method for Estimating the Probability of Adverse Drug Reaction," <u>Clinical</u> Pharmacology and Therapeutics 30.2 (August 1981): 239-245				
		Pestotnick SL, et al., "Medical Informatics: Meeting the Information Challenges of a Changing Health Care System," <u>Journal of Informed Pharmacotherapy</u> 2 (2000): 1				
	Pestotnik S, "The Future of ID Pha [editorial] Society of Infectious Diseas					
	Pestotnik SL, (August 1993). "Compunpublished masters thesis, University					
	Quality of the Medication Use Proces	unpublished masters thesis, University of Utah, Salt Lake City, Utah, United States: 1-62 Pestotnik SL, "Role of Information Systems in Reducing Adverse Drug Events," <u>Improving the Quality of the Medication Use Process: Error Prevention & Reducing Adverse Drug Events</u> . New York: Pharmaceutical Products Press/Haworth Press, Inc. (1998): 183-91				

FORM PTO-1449	Atty. Docket No.: 15226.25.1	Serial No.: 10/773,106		
	Applicant:			
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATIONDISCLOSURE	William J. Ketcherside, Jr. e	t al.		
STATEMENT	Filing Date:	Group Art:		
	02/05/2004	2632		
				
Pestotnik SL, et al., "A Five-Year A Hospital," Abstracts of the 33 rd ICAAC	Analysis of Parental Anti-inf C. New Orleans, LA (October	ective Use at a Tertiary Care 17-20, 1993), 634: 235		
Pestotnik SL, et al., "Adverse Effect Attributable Costs and Excess Length of 35 th Annual Meeting 25.2 (August 199	of Stay," Clinical Infectious D	n (IVV) in Hospital Patients: Diseases, Abstracts of the IDSA		
Pestotnik SL, et al., "Expert Clinic Stewardship Programs," Pharmacother	cal Decision Support System apy 25.8 (2005): 1116-25	ns to Enhance Antimicrobial		
Pestotnik SL, et al., "Expert Clinic Stewardship Programs," Society of Info 2-7	Pestotnik SL, et al., "Expert Clinical Decision Support Systems to Enhance Antimicrob Stewardship Programs," <u>Society of Infectious Diseases Pharmacists Newsletter</u> 14.3 (Winter 200: 2-7			
Pestotnik SL, et al., "Medical Inform Perspective," <u>International Pharmace</u> 3505425: 817	Pestotnik SL, et al., "Medical Informatics, Decision Support, and Quality of Care: Clinician Perspective," <u>International Pharmaceutical Abstracts</u> , Information Processing and Literatur 3505425: 817			
Pestotnik SL, et al., "Prospective Surve Using a Hospital Information System,"				
Hospitalized Patients," Abstracts of	of Imipenem-associated Seizures in a Large Cohort of the 1992 ICAAC, The 32 nd Interscience Conference on apy. Anaheim, CA (October 11-14, 1992), 530: 199			
Pestotnik SL, et al., "Therapeutic A Expert System," American Journal of				
Riley DK, et al., "The Effect of Improv Microbial Resistance Patterns," Infection	ed Prophylactic and Therapeu on Control and Hospital Epide	tic Antibiotic Use on Hospital miology, S2 (April 1994): P26		
(CDSS) Utilized by the Rural Antibiot	Tettelbach W, et al., "Usage Evaluation of a Computerized Clinical Decision Support System (CDSS) Utilized by the Rural Antibiotic Decision-Support & Resistance (RADAR) Project," upon information and belief, available at least as early as 2001			
	Pestotnik SL, "E-Prescribing in the Hospital with the Theradoc System," 44 th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC (October 30-November 2, 2004), (abst. 636)			
Classen DC, et al., "Antibiotic Outcom Use in Hospitalized Patients," Clin. Res	nes Research: A Large Rando <u>s.</u> 39.2 (1991): 373A	omized Trial of Cephalosporin		
Tettlebach WH, et al., "Usage Evaluati System," 42 nd ICAAC Abstracts, 42 Chemotherapy. San Diego, CA (Septer	^{na} Interscience Conference o	on Antimicrobial Agents and		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.